Skip to main content
. 2021 May 4;21:230. doi: 10.1186/s12888-021-03230-1

Table 1.

Demographic and neuropsychological performances in patients with AOS and healthy controls (M ± SD)

Items Patients with AOS Healthy controls T/x2 P value
Number of participants 71 53
Gender (male/female) 40/31 23/30 2.034 0.154
Age (years) 16.11 ± 1.38 15.80 ± 0.87 1.649 0.102
Educational year 9.87 ± 1.47 10.47 ± 0.82 −1.688 0.094
MoCA 27.67 ± 1.99 28.6 ± 1.49 −2.495 0.015*
Stroop Color 17.02 ± 5.39 12.25 ± 2,78 6700 < 0.001***
Stroop Word 20.30 ± 7.02 14.68 ± 3.90 5940 < 0.001***
Stroop Color&Word 33.16 ± 13.46 26.34 ± 9.05 3.546 0.001***
DS-Forward 7.96 ± 0.25 7.96 ± 0.18 −0.069 0.945
DS-Backward 5.45 ± 1.15 6.31 ± 0.84 −4.677 < 0.001***
PANSS-P 13.81 ± 6.27
PANSS-N 13.44 ± 6.45
PANSS-T 54.81 ± 14.77
CPZeq of total antipsychotic drugs (mg/day) 441.55 ± 115.76

Note: MoCA Montreal Cognitive Assessment; Stroop Stroop Color Word Tasks; PANSS Positive and Negative Syndrome Scale. PANSS - P PANSS Positive Subscale Score; PANSS - N PANSS Negative Subscale Score; PANSS - T PANSS Total Score; DS The Digital Span Test, CPZ - eq Chlorpromazine - equivalent.* p < 0.05, *** p < 0.001